Rua Bioscience Ltd. · NZX:RUA
Rua Bioscience — Shareholder Meeting (November 2024)
34 slides from Rua Bioscience's shareholder meeting presentation, Nov 4, 2024
Slide 1: Hui a Tau Annual Shareholders Meeting
Hui a Tau Annual Shareholders Meeting 4th November 2024
Slide 2: Disclaimer
Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a leading distributor of cannabinoid derived medicines. This presentation and the information contained in or accompanying this presentation are not, and are under no circumstances to be construed as, an invitation to
Slide 3: How to participate in virtual/hybrid meetings (Q&A)
How to participate in virtual/hybrid meetings (Q&A) Shareholder and proxyholder Q&A participation Written questions Questions may be submitted ahead of the meeting. If you have a question to submit during the live meeting, please select the Q&A tab on the right half of your screen at any time. Type
Slide 4: How to participate in virtual/hybrid meetings (Voting)
How to participate in virtual/hybrid meetings (Voting) Shareholder and proxyholder voting Once the voting has been opened, the resolutions and voting options will allow voting. To vote, simply click on the Vote tab, and select your voting direction from the options shown on the screen. You can vote
Slide 5: Board of Directors Te Poari Ringatohu
Board of Directors Te Poari Ringatohu Anna Stove Panapa Ehau Teresa Ciprian Tony Barclay Kale Panoho Chair Executive Director, Non-Executive Director Non-Executive Director Board Observer Co-Founder A 25+ years track record leading Co-founder of a number of social Global expertise in innovation, Ove
Slide 6: Agenda
Agenda 1. Company overview and Chair’s address Rarangi take 2. Chief Executive Officer’s presentation 3. Annual results presentation 4. Shareholder questions 5. Ordinary resolutions a) Auditor’s remuneration b) Issue of New Ordinary Shares 6. General business
Slide 7: Company overview and Chair's address
Company overview and Chair’s address Te tirohanga whanui o te kamupene me te korero a te Heamana
Slide 8: Rua's unique growth strategy
Unique genetics selected at Ruatorea Rua’s unique growth strategy Te rautaki whakatupu ahurea o Rua Partner with best in class for low cost, scalable delivery. We work with cultivation and • Capital-light approach manufacturing companies closer to our key markets. This • R&D and genetic discovery in
Slide 9: Achievements at a glance
Achievements at a glance Mawhiti mai ki nga whakatutukitanga Established short-term revenue Extended the distribution Achieved first revenues Signed a distribution agreement Received approval from Secured agreements pipelines to fill with unique contract with Nimbus Health in in Australia, and devel
Slide 10: rs o WY > we " d “a
rs o WY > we " d 7 7 “a Wf 1 fi V > y - y. mY WZ ~ Me Aa eee 7 ee Si) / 5 yv A . . RUA
Slide 11: Rua requires additional capital to fund growth opportunities
Rua requires additional capital to fund growth opportunities Rua is seeking to raise ~NZ$3,1m of new equity – Working capital funding for growth – The cash raised, both from the facility sale and capital raise, is intended (if fully subscribed) to fund the business to a self-sustaining position. 11
Slide 12: Chief Executive Officer's presentation
Chief Executive Officer’s presentation Te whakatakotoranga o te Kaiwhakahaere Matua
Slide 13: FY24: An overview
Unique genetics selected at Ruatorea. FY24: An overview Tirohanga whanui Partner with best in class for low cost, scalable delivery. We work with cultivation and manufacturing companies closer to our key markets. This allows Rua to grow our revenues in a capital-light • Established sales footprint i
Slide 14: Global progress
Aotearoa New Zealand Two new products approved. Australia First sales in FY24, established new distribution United Kingdom channels. Poland United Kingdom Signed distribution agreement with Target Germany Czechia Healthcare. Germany Extended contract with Nimbus Health and established supply. Global
Slide 15: Germany
Germany • Largest and most developed medicinal cannabis market in Europe, if not the world. • Changes in regulations in April 2024 saw considerable growth in the market. • Extended agreement with Nimbus Healthcare for an additional three year term. • July 24 we launched a new dried flower product wh
Slide 16: Australia
Australia • One of the larger medicinal cannabis markets in the world at approx. $450m. • In August 2023 we took delivery of our first product and made it available for sale. • We employed our first Australian based employee, John Sanders as the Chief of Sales and Marketing to drive sales and reinfo
Slide 17: United Kingdom
United Kingdom • Signed distribution agreement with Target Healthcare • Have subsequently established a supply pipeline meeting the necessary regulatory requirements. • Products expected in the market in November 24 17
Slide 18: Aotearoa New Zealand
Aotearoa New Zealand • We received approval for two dried flower products from the Ministry of Health • First sales in July 24. • New product expected in November 24 • Two further product applications have been initiated. 18
Slide 19: Impact Programme
Impact Programme Nga hotaka whakaawe Compassionate Access Programme • In FY24 we expanded the programme through the support of our supply network and partners to 52 patients per month.
Slide 20: Impact Programme
Impact Programme Nga hotaka whakaawe Scholarship Programme Focusing on inspiring the next generation of scientists and entrepreneurs. • 12 scholarships awarded • 2 Industry trips to Auckland and Wellington • 1 Internship • 3 Kura visits to Mangaoporo
Slide 21: Rua's FY24 GHG report
Rua’s FY24 GHG report Te ripoata GHG o Rua mo FY24 • Scope 1 and 2 emissions reduced by 20% • Scope 3 emissions a challenge
Slide 22: Our plans for FY25
Our plans for FY25 Te mahere o Rua FY25 Revenue from customers $3–5 mill New products Legacy genetics to Germany and Australia Two new products in New Zealand and Germany New markets United Kingdom
Slide 23: FY24 financial commentary
FY24 financial commentary Nga korero mo nga putea
Slide 24: Financial commentary: Profit & loss
Financial commentary Rua establishes in all Profit & loss markets Nga korero mo nga putea Rua’s annual financial results for the Revenue from customers year ended 30 June 2024. $86k Total revenue and other income $322k Loss before tax -$13.7m
Slide 25: Financial commentary: Balance sheet
Financial commentary Rua requires further Balance sheet capital Nga korero mo nga putea Cash and investments Rua’s annual financial results for the year ended 30 June 2023. $0.90m Total assets $7.74m Total liabilities $0.97m Net assets $6.77m
Slide 26: Financial commentary: Cashflow
Financial commentary Investing in the future Cashflow Nga korero mo nga putea Rua’s annual financial results for the Net cash outflow from operating activities year ended 30 June 2024. $3.74m Net cash inflow from investing activities $2.21m Net cash outflow from financing activities $95k
Slide 27: Financial commentary: Operational expenditure
Financial commentary Operational expenditure Nga korero mo nga putea $608 $509 Rolling 12month average monthly expenditure ($000) $334 Jun-22 Jun-23 Jun-24
Slide 28: Financial commentary: Sales Revenue
Financial commentary Sales Revenue Nga korero mo nga putea $225 Quarterly sales revenue, all markets ($000) $45 $15 $23 $3 Q1 Q2 Q3 Q4 Q1 FY24 FY25
Slide 29: Shareholder questions
Shareholder questions Nga patai a nga kaipupuri hea
Slide 30: Ordinary resolutions
Ordinary resolutions Whakataunga noa
Slide 31: Resolution One
Resolution One That the Board be authorised to fix the auditor’s remuneration.
Slide 32: Resolution Two
Resolution Two ThatThat AnnatheStove Boardbeare authorised re-elected as atoDirector issue New Shares of Rua. • Up to 37,311,522 shares • At a price of not less than 3c per share • At any time during the next 12 months
Slide 33: General business
General business Nga take hakirikiri
Slide 34: Rua Bioscience
RUA BIOSCIENCE